TS DNA Sharing Repository Hosts State-of-the-art Treatment Talk about Tourette Syndrome

PRLog (Press Release) - Sep 10, 2008 -
FOR IMMEDIATE RELESE            
Contact: Nicole Greco- NJCTS- 908.575.7350          

September 10, 2008

STATE OF THE ART TREATMENTS FOR TOURETTE SYNDROME AND ASSOCIATED CONDITIONS AT TS DNA SHARING REPOSITORY
Including attention deficit and obsessive-compulsive disorders

Somerville, N.J.- New pathways to treating Tourette Syndrome and its associated neurological disorders will be discussed by Robert A. King, MD on September 19, from 5-6 p.m. at Rutgers University in Piscataway. Dr. King is part of New Jersey Center for Tourette Syndrome- a partnership between the Tourette Syndrome Association of New Jersey, Rutgers University and medical professionals throughout New Jersey.

  Tourette Syndrome is a neurological disorder, most commonly expressed in motor of vocal tics that affects as many as 28,000 children and families throughout New Jersey.  Aside from providing support to those with TS, NJCTS has established the world’s first TS DNA Sharing Repository, and the world’s first student-run stand-alone TS Clinic- both at Rutgers University.

  Dr. King is taking part in the genetic study of Tourette Syndrome and on September 19th he will present recent clinical advances in medication and other state-of-the-art  treatments for Tourette Syndrome and other associated disorders. Dr. King will answer questions and describe the ongoing genetic research study by NJCTS.

 Dr. King wills Medical Director of Tourette/OCD/Anxiety Disorder Clinic at the Yale University Child Study Center where he is also Professor of Child Psychiatry. He is the author of numerous scientific papers and wrote the American Academy of Child and Adolescent Psychiatry’s Practice Parameter on Assessment and Treatment of Childhood OCD.